-
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
04 Apr 2024 20:58 GMT
… of clinical-stage biotechs like Disc Medicine, Inc. IRON and … efficacy compared to epoetin alfa in the study… 2 clinical trial.
VNDA Up on Drug Approval: Vanda Pharmaceuticals Inc.… FDA approval of Fanapt (iloperidone) tablets for the acute treatment …
-
Bristol Myers Squibb's Reblozyl gets European expanded approval to include first─line treatment of transfusion─dependent anaemia in adults with LR─MDS
04 Apr 2024 06:19 GMT
… need for more effective treatment options to address the … significant milestone towards improving treatment practice and offering better … of Reblozyl versus epoetin alfa for the treatment of anaemia … research is to deliver medicines that offer each patient …
-
REBLOZYL for the Treatment of Anaemia Associated with Beta-Thalassemia, US
03 Apr 2024 05:26 GMT
… Medicines Agency recommended approval of REBLOZYL as a treatment … RBCs.
Clinical trials on REBLOZYL
The US FDA approval of … randomised, placebo-controlled clinical trial named BELIEVE, which compared … of the drug versus epoetin alfa for the treatment of the …
-
EC approves Bristol Myers Squibb’s Reblozyl for first-line MDS treatment
03 Apr 2024 11:51 GMT
… ) as a first-line treatment for adults with transfusion-dependent … trial assessed the efficacy and safety of Reblozyl compared to epoetin … a first-in-class treatment for people with disease- … for the first-line treatment of anaemia associated with …
-
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
03 Apr 2024 00:16 GMT
… Reblozyl versus epoetin alfa for the treatment of anemia … new frontiers in personalized medicine and, through innovative … development and commercialization of pharmaceutical products. All statements … clinical benefit in confirmatory trials, and whether such …
-
Erythropoietin Drugs Market Expected To Witness Huge Revenue Growth To 2028
13 Mar 2024 09:31 GMT
… .
Anemia Treatment: EPO drugs play a … drugs as the global population ages.
Market Segmentation:
Types: Epoetin …
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy … trials exploring the potential applications of Erythropoietin drugs …
-
Erythropoietin Drugs Market growing significantly at 8.1% CAGR with $330.9 million by 2031
04 Mar 2024 12:50 GMT
… from ESRD treatments and dialysis procedures. EPO drugs have gained … Erythropoietin Drugs Market Report Highlights:
By PRODUCTS:
Epoetin-alfa
Epoetin-beta
… Key Market Players:
INTAS PHARMACEUTICALS, TEVA PHARMACEUTICAL INDUSTRIES LTD., BIOCON, …
-
Drug Trials Snapshots: JESDUVROQ
22 Feb 2024 19:13 GMT
… trials that supported the original FDA approval of this drug … make decisions regarding medical care. Always speak … treatment (epoetin alfa and darbepoetin alfa) for both endpoints.
How were the trials … trial.
PLACEBO: An inactive substance or “sugar pill” …
-
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
23 Feb 2024 12:33 GMT
… pivotal Phase 3 COMMANDS trial. Results from the … Reblozyl versus epoetin alfa for the treatment of anemia … new frontiers in personalized medicine and, through innovative … development and commercialization of pharmaceutical products. All statements that …
-
Erythropoietin Drugs Market to Garner $14.41 Billion by 2028 and CAGR of 5.7%
14 Feb 2024 07:28 GMT
… such patients, requiring EPO treatment. Despite this, the … the demand for medical services including erythropoietin. … Ltd.
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy Laboratories … presence of generic epoetin products. Asia-Pacific …